Onconetix (ONCO) Share-based Compensation (2021 - 2026)

Onconetix (ONCO) has reported Share-based Compensation for 6 consecutive years, with $24.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 78050.72% year-over-year to $24.2 million in Q2 2026; TTM through Jun 2026 was $24.2 million, a 252.97% increase from a year earlier, with the FY2025 full-year figure at $24.6 million, up 5510.07% from the prior year.
• Share-based Compensation was $24.2 million for Q2 2026 at Onconetix, roughly flat from $24.2 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $24.2 million in Q1 2026 and troughed at $4234.0 in Q4 2025.
• A 5-year average of $4.5 million and a median of $759706.5 in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation plunged 98.76% in 2025 and jumped 78050.72% in 2026, its largest moves.
• Over 5 years, Share-based Compensation stood at $178298.0 in 2022, then jumped by 3513.47% to $6.4 million in 2023, then tumbled by 94.72% to $340425.0 in 2024, then sank by 98.76% to $4234.0 in 2025, then jumped by 571762.42% to $24.2 million in 2026.
• The last three Share-based Compensation figures came in at $24.2 million (Q2 2026), $24.2 million (Q1 2026), and $4234.0 (Q4 2025), per Business Quant data.